Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2,000
Single User License Price INR 135
Corporate User License Price USD 6,000
Corporate User License Price INR 405
Site License Price USD 4,000
Site License Price INR 270
Request a Quote

Report Title

Diabetic Retinopathy - Pipeline Review, H1 2018

Quote Request for License Type
License Type Price  
Single User License USD 2,000
Site License USD 4,000
Enterprise Wide License USD 6,000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Diabetic Retinopathy - Pipeline Review, H1 2018


Quote Request for License Type
License Type Price  
Single User License USD 2,000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Diabetic Retinopathy - Pipeline Review, H1 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Diabetic Retinopathy - Pipeline Review, H1 2018



Executive Summary

Diabetic Retinopathy - Pipeline Review, H1 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H1 2018, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

 

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 7, 47, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.

 

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Retinopathy - Overview 6

Diabetic Retinopathy - Therapeutics Development 7

Diabetic Retinopathy - Therapeutics Assessment 18

Diabetic Retinopathy - Companies Involved in Therapeutics Development 29

Diabetic Retinopathy - Drug Profiles 46

Diabetic Retinopathy - Dormant Projects 194

Diabetic Retinopathy - Discontinued Products 198

Diabetic Retinopathy - Product Development Milestones 199

Appendix 209

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Diabetic Retinopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

List of Tables

Number of Products under Development for Diabetic Retinopathy, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Diabetic Retinopathy - Pipeline by Abzena Plc, H1 2018

Diabetic Retinopathy - Pipeline by Acucela Inc, H1 2018

Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H1 2018

Diabetic Retinopathy - Pipeline by Applied Therapeutics Inc, H1 2018

Diabetic Retinopathy - Pipeline by Araim Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by BCN Peptides SA, H1 2018

Diabetic Retinopathy - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Diabetic Retinopathy - Pipeline by Charlesson LLC, H1 2018

Diabetic Retinopathy - Pipeline by Coherus BioSciences Inc, H1 2018

Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H1 2018

Diabetic Retinopathy - Pipeline by Dynamis Therapeutics Inc, H1 2018

Diabetic Retinopathy - Pipeline by EyeGene Inc, H1 2018

Diabetic Retinopathy - Pipeline by EyePoint Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Diabetic Retinopathy - Pipeline by Formycon AG, H1 2018

Diabetic Retinopathy - Pipeline by IMMD Inc, H1 2018

Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc, H1 2018

Diabetic Retinopathy - Pipeline by Kowa Co Ltd, H1 2018

Diabetic Retinopathy - Pipeline by Lupin Ltd, H1 2018

Diabetic Retinopathy - Pipeline by M's Science Corp, H1 2018

Diabetic Retinopathy - Pipeline by Mabion SA, H1 2018

Diabetic Retinopathy - Pipeline by Medy-Tox Inc, H1 2018

Diabetic Retinopathy - Pipeline by Nemus Bioscience Inc, H1 2018

Diabetic Retinopathy - Pipeline by NGM Biopharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by Oculis ehf, H1 2018

Diabetic Retinopathy - Pipeline by OcuNexus Therapeutics Inc, H1 2018

Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc, H1 2018

Diabetic Retinopathy - Pipeline by PanOptica Inc, H1 2018

Diabetic Retinopathy - Pipeline by Profarma, H1 2018

Diabetic Retinopathy - Pipeline by Promedior Inc, H1 2018

Diabetic Retinopathy - Pipeline by Protheragen Inc, H1 2018

Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Diabetic Retinopathy - Pipeline by Rezolute Inc, H1 2018

Diabetic Retinopathy - Pipeline by Ribomic Inc, H1 2018

Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc, H1 2018

Diabetic Retinopathy - Pipeline by Sylentis SAU, H1 2018

Diabetic Retinopathy - Pipeline by ThromboGenics NV, H1 2018

Diabetic Retinopathy - Pipeline by Unity Biotechnology Inc, H1 2018

Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H1 2018

Diabetic Retinopathy - Dormant Projects, H1 2018

Diabetic Retinopathy - Dormant Projects, H1 2018 (Contd..1), H1 2018

Diabetic Retinopathy - Dormant Projects, H1 2018 (Contd..2), H1 2018

Diabetic Retinopathy - Dormant Projects, H1 2018 (Contd..3), H1 2018

Diabetic Retinopathy - Discontinued Products, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Abzena Plc

Acucela Inc

Aerie Pharmaceuticals Inc

Antisense Therapeutics Ltd

Applied Therapeutics Inc

Araim Pharmaceuticals Inc

BCN Peptides SA

Boehringer Ingelheim GmbH

Charlesson LLC

Coherus BioSciences Inc

Crinetics Pharmaceuticals Inc

Dimerix Bioscience Pty Ltd

Dynamis Therapeutics Inc

EyeGene Inc

EyePoint Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Formycon AG

IMMD Inc

Kodiak Sciences Inc

Kowa Co Ltd

Lupin Ltd

M's Science Corp

Mabion SA

Medy-Tox Inc

Nemus Bioscience Inc

NGM Biopharmaceuticals Inc

Oculis ehf

OcuNexus Therapeutics Inc

Ohr Pharmaceutical Inc

PanOptica Inc

Profarma

Promedior Inc

Protheragen Inc

Regeneron Pharmaceuticals Inc

Rezolute Inc

Ribomic Inc

Strongbridge Biopharma plc

Sylentis SAU

ThromboGenics NV

Unity Biotechnology Inc

VESSL Therapeutics Ltd

Diabetic Retinopathy Therapeutic Products under Development, Key Players in Diabetic Retinopathy Therapeutics, Diabetic Retinopathy Pipeline Overview, Diabetic Retinopathy Pipeline, Diabetic Retinopathy Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand